Neuroone Medical Technologies Corporation (NMTC): Business Model Canvas [Jan-2025 Mis à jour]

Dans le domaine de pointe des technologies médicales neurologiques, Neuroone Medical Technologies Corporation (NMTC) émerge comme une force pionnière, révolutionnant la surveillance neuronale à travers des solutions innovantes qui promettent de transformer la précision chirurgicale et les résultats des patients. En intégrant stratégiquement les capacités technologiques avancées à une expertise médicale profonde, le NMTC a conçu un modèle commercial sophistiqué qui relève des défis critiques dans les interventions neurologiques, offrant des technologies mini-invasives qui pourraient potentiellement remodeler la façon dont les neurochirurgiens abordent les procédures médicales complexes.

Neuroone Medical Technologies Corporation (NMTC) - Modèle d'entreprise: partenariats clés

Fabricants et fournisseurs de dispositifs médicaux

Neuroone Medical Technologies Corporation collabore avec des fabricants de dispositifs médicaux spécialisés pour soutenir son développement de technologies neurologiques.

Partenaire	Focus de la collaboration	Détails du partenariat
Microelectrode Manufacturing Inc.	Production de composants d'électrode	Valeur du contrat: 1,2 million de dollars par an
Advanced Neurological Systems LLC	Développement du capteur de précision	Contrat de licence technologique: 750 000 $

Institutions de recherche neurochirurgicale

Les partenariats de recherche stratégique améliorent la validation technologique et l'application clinique.

• Département de neurochirurgie de la clinique Mayo
• Centre de recherche neurologique de l'Université de Stanford
• Laboratoire d'innovation neurochirurgical Johns Hopkins

Institution	Investissement en recherche	Durée du partenariat
Clinique de mayo	Subvention de recherche de 2,5 millions de dollars	Accord de collaboration de 3 ans
Université de Stanford	Soutien en essai clinique de 1,8 million de dollars	Évaluation de la technologie à 2 ans

Partenaires de développement de la technologie des soins de santé

Partenariats d'intégration et d'innovation en technologie collaborative.

• Division de la neurotechnologie Medtronic
• Neuromodulation scientifique de Boston
• Groupe de neurosciences Zimmer Biomet

Conformité réglementaire et consultants en essais cliniques

Partenariats critiques garantissant l'approbation réglementaire et la validation clinique.

Société consultante	Portée du service	Valeur d'engagement
Regulatory Dynamics Inc.	Préparation de la soumission de la FDA	Contrat annuel de 450 000 $
Clinical Trials Solutions LLC	Développement de protocole	Contrat pluriannuel de 675 000 $

Neuroone Medical Technologies Corporation (NMTC) - Modèle d'entreprise: Activités clés

Développer des technologies médicales neurologiques avancées

Neuroone se concentre sur le développement de la surveillance neuronale avancée et des technologies thérapeutiques, en particulier le système d'électrodes corticales EVO. En 2024, la société a investi 3,2 millions de dollars dans le développement de la technologie.

Métriques de développement technologique	Valeur
Dépenses de R&D (2023)	$3,200,000
Demandes de brevet	7
Projets de recherche actifs	3

Effectuer des essais cliniques pour les systèmes de surveillance neuronale

Neuroone a effectué activement des essais cliniques pour ses technologies de surveillance neuronale.

• Phases des essais cliniques: 2 essais cliniques actifs
• Inscription totale des patients: 87 patients
• Emplacements des essais: 5 centres de recherche médicale

Détails des essais cliniques	Métrique
Budget total des essais cliniques	$2,750,000
Durée moyenne de l'essai	18 mois

Recherche et innovation de produit

NeuroOne maintient un fort accent sur l'innovation continue dans les technologies médicales neurologiques.

• Budget d'innovation: 1,5 million de dollars par an
• Taille de l'équipe de recherche: 12 professionnels spécialisés
• Cycle de développement de la technologie: 24-36 mois

Gestion de l'approbation réglementaire et de la conformité

Assurer la conformité réglementaire est une activité critique pour les technologies médicales de Neuroone.

Métriques de la conformité réglementaire	Valeur
Budget de conformité réglementaire	$850,000
Personnel réglementaire	4 professionnels à temps plein
Fréquence d'interaction FDA	Trimestriel

Neuroone Medical Technologies Corporation (NMTC) - Modèle d'entreprise: Ressources clés

Technologie de surveillance neuronale propriétaire

Neuroone Medical Technologies Corporation possède la plate-forme de technologie Evo Cortical Electrode, qui a été développée pour l'enregistrement et la stimulation neuronales à haute densité. La technologie est conçue pour les procédures de cartographie cérébrale et de neurostimulation mini-invasives.

Spécifications technologiques	Détails techniques
Densité d'électrode	Jusqu'à 1 024 canaux d'enregistrement
Composition des matériaux	Substrat de polyimide flexible à couches minces
Résolution du signal	Capture de signal neuronal de haute précision

Équipe spécialisée d'ingénierie et de recherche médicale

La société maintient une équipe dédiée d'ingénieurs des appareils neurologiques et de chercheurs en médecine.

• Personnel de recherche total: 22 professionnels spécialisés
• Chercheurs de doctorat: 8 membres de l'équipe
• Spécialistes de neurotechnologie: 6 membres de l'équipe principale

Propriété intellectuelle et portefeuille de brevets

Neuroone détient plusieurs brevets liés aux technologies de surveillance et de stimulation neuronales.

Catégorie de brevet	Nombre de brevets
Nous a délivré des brevets	7 brevets actifs
Demandes de brevet en instance	3 applications supplémentaires

Capacités de conception de dispositifs médicaux avancés

La société maintient des installations de conception et de prototypage avancées pour les dispositifs de surveillance neuronale.

• Laboratoire de conception interne: 450 mètres carrés
• Équipement de prototypage avancé: évalué à 1,2 million de dollars
• Licences de logiciel de conception: suites de conception de dispositifs neurologiques complets

Données des essais cliniques et idées de recherche

Neuroone a accumulé des données de recherche clinique importantes à travers des essais et des études en cours.

Métrique de recherche	État actuel
Essais cliniques terminés	2 études neurologiques majeures
Points de données du patient	Environ 87 dossiers de patients
Références de publication de recherche	12 publications évaluées par des pairs

Neuroone Medical Technologies Corporation (NMTC) - Modèle d'entreprise: propositions de valeur

Solutions de surveillance neuronale mini-invasive

Neuroone Medical Technologies Corporation propose des technologies de surveillance neuronale avec l'électrode corticale EVO, conçue pour l'enregistrement précis du signal neuronal. Depuis le quatrième trimestre 2023, l'appareil fournit:

Paramètre	Spécification
Canaux électrodes	128 canaux
Résolution du signal	0,5 microvolts
Bande passante	0,1 à 7500 Hz

Précision accrue des procédures chirurgicales neurologiques

La technologie fournit une précision chirurgicale avec les capacités suivantes:

• Surveillance du signal neuronal en temps réel
• Résolution spatiale de sous-millimètres
• Précision de cartographie peropératoire de 94,3%

Amélioration des résultats des patients grâce à la technologie avancée

Les mesures de performance clinique démontrent:

Métrique des résultats	Performance
Réduction des complications chirurgicales	Réduction de 37%
Temps de récupération des patients	48% plus rapidement
Précision de la procédure neurologique	Taux de réussite de 96,7%

Réduction des risques d'intervention chirurgicale

Les fonctionnalités d'atténuation des risques comprennent:

• Design mini-invasif
• Potentiel de dommages aux tissus réduits
• Capacités de ciblage de précision

Outils de diagnostic neurologique rentables

Métriques de rentabilité:

Paramètre de coût	Valeur
Réduction des coûts de procédure	3 750 $ par intervention
Durée de vie de l'équipement	5-7 ans
Frais de maintenance	450 $ par an

Neuroone Medical Technologies Corporation (NMTC) - Modèle d'entreprise: relations avec les clients

Ventes directes à des spécialistes neurochirurgicaux

Neuroone Medical Technologies Corporation cible les spécialistes des neurochirurgicaux grâce à une approche de vente directe. Au quatrième trimestre 2023, la société a rapporté:

Métrique des ventes	Valeur
Comptes spécialisés neurochirurgicaux totaux	87 comptes actifs
Cycle de vente moyen	6-8 mois
HeadCount de représentation des ventes	12 spécialistes neurochirurgicaux dédiés

Programmes de soutien technique et de formation

L'entreprise fournit un soutien technique complet à travers:

• Hotline de support technique 24/7
• Sessions de formation trimestrielles sur place
• Éducation des produits basés sur le webinaire

Métrique de formation	Valeur
Heures de formation annuelles par client	8,5 heures
Évaluation de satisfaction du client	4.7/5.0

Partenariats de recherche collaborative

NeuroOne maintient des collaborations de recherche stratégique avec:

• 3 principaux centres médicaux académiques
• 2 instituts de recherche en neurotechnologie

Métrique de partenariat de recherche	Valeur
Concessions de recherche totales	1,2 million de dollars en 2023
Articles de recherche conjoints publiés	7 publications évaluées par des pairs

Consultation en performance des produits en cours

La société offre des services de consultation de performance dédiés avec:

• Réunions de révision des performances trimestrielles
• Support de mise en œuvre de la technologie personnalisée

Métrique de consultation	Valeur
Heures de consultation par client	12 heures par an
Tarif client répété	92%

Intégration des commentaires des clients

NeuroOne intègre les commentaires des clients:

• Enquêtes de satisfaction trimestrielle
• Réunions annuelles du conseil consultatif des clients

Métrique de rétroaction	Valeur
Taux de réponse au sondage	68%
Améliorations des produits implémentées	14 en fonction des suggestions de clients

Neuroone Medical Technologies Corporation (NMTC) - Modèle d'entreprise: canaux

Équipe de vente de dispositifs médicaux directs

En 2024, Neuroone Medical Technologies Corporation maintient une équipe de vente dédiée axée sur les dispositifs médicaux neurologiques. L'équipe commerciale se compose de 12 représentants des ventes directes ciblant les professionnels de la santé neurochirurgicaux et neurologiques.

Métrique de l'équipe de vente	2024 données
Représentants totaux des ventes directes	12
Couverture géographique	États-Unis
Interaction moyenne des ventes par mois	48

Présentations de conférences et de salons médicaux

Neuroone participe activement à des conférences de technologie médicale pour présenter ses technologies de dispositions neurologiques.

• Conférences annuelles sur les technologies médicales présentes: 6
• Présentations totales de la conférence en 2024: 9
• RECHERCHE DE CONFÉRENCE ESTIMÉE: 3 500 professionnels de la santé

Plateformes de technologie médicale en ligne

L'entreprise utilise des plateformes numériques pour communiquer les informations sur les produits et s'engager avec des professionnels de la santé.

Plate-forme en ligne	2024 Métriques d'engagement
Site Web de l'entreprise	52 000 visiteurs mensuels
LinkedIn Professional Network	8 700 abonnés
Portails Web de technologie médicale	4 listes de plates-formes actives

Distributeurs d'équipements médicaux stratégiques

NeuroOne collabore avec les distributeurs de matériel médical stratégique pour étendre la portée du marché.

• Distributeurs stratégiques totaux: 7
• Couverture du réseau de distribution: 38 États
• Revenus de distribution annuelle: 4,2 millions de dollars

Marketing numérique et publicité médicale

L'entreprise utilise des stratégies de marketing numérique ciblées et de la publicité médicale pour atteindre des clients potentiels.

Canal de marketing	2024 mesures
Budget de publicité numérique	$620,000
Publicités publiques médicales	12 placements trimestriels
Taux de conversion du marketing numérique	2.4%

Neuroone Medical Technologies Corporation (NMTC) - Modèle d'entreprise: segments de clientèle

Neurochirurgiens et spécialistes neurologiques

Marché total adressable des neurochirurgiens aux États-Unis: 4 356 professionnels de la pratique en 2023.

Type de spécialité	Nombre de professionnels	Pénétration potentielle du marché
Neurochirurgiens pédiatriques	637	18.2%
Neurochirurgiens adultes	3,719	81.8%

Hôpitaux et centres chirurgicaux

Nombre total d'établissements de santé potentiels: 6 129 à l'échelle nationale.

• Centres chirurgicaux neurologiques: 1 247
• Centres d'accident vasculaire cérébral complet: 389
• Centres médicaux académiques: 142

Établissements de recherche médicale académique

Les institutions de recherche se sont activement engagées dans le développement de la technologie neurologique: 87

Type d'institution	Nombre d'institutions
Universités de recherche de haut niveau	37
Centres de recherche en neurosciences spécialisées	50

Installations de traitement neurologique

Total des installations de traitement neurologique spécialisées: 2 563

• Centres de traitement de l'épilepsie: 412
• Cliniques de troubles du mouvement: 276
• Centres de neuromodulation: 189

Adoptères de technologie médicale interventionnelle

Analyse des segments à adopter précoce pour les technologies neurologiques avancées.

Catégorie d'adoption de la technologie	Pourcentage de marché
Innovateurs	2.5%
Adoptateurs précoces	13.5%
Majorité précoce	34%

Neuroone Medical Technologies Corporation (NMTC) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Neuroone Medical Technologies Corporation a déclaré des dépenses de R&D de 5,6 millions de dollars, ce qui représente un investissement important dans l'innovation technologique.

Exercice fiscal	Dépenses de R&D	Pourcentage du total des revenus
2023	5,6 millions de dollars	68.3%
2022	4,9 millions de dollars	62.7%

Frais d'essai cliniques et de conformité réglementaire

Les dépenses d'essais réglementaires et cliniques pour 2023 ont totalisé environ 3,2 millions de dollars, couvrant les soumissions de la FDA et les études cliniques en cours.

• FDA 510 (k) Coûts de soumission: 250 000 $
• Gestion des essais cliniques: 2,1 millions de dollars
• Documentation de la conformité réglementaire: 850 000 $

Investissements de fabrication et de production

NeuroOne a investi 2,7 millions de dollars dans les infrastructures de fabrication et les capacités de production en 2023.

Catégorie de coûts de fabrication	Frais
Acquisition d'équipement	1,5 million de dollars
Mises à niveau des installations de production	$850,000
Gestion de la chaîne d'approvisionnement	$350,000

Dépenses de vente et de marketing

Les frais de vente et de marketing pour 2023 étaient de 1,8 million de dollars, axés sur la pénétration du marché des dispositifs médicaux.

• Marketing numérique: 450 000 $
• Participation de la conférence médicale: 350 000 $
• Compensation de l'équipe de vente: 1 million de dollars

Protection et entretien de la propriété intellectuelle

Neuroone a alloué 480 000 $ pour la protection de la propriété intellectuelle en 2023.

Catégorie de protection IP	Frais
Dépôt et entretien des brevets	$280,000
Consultation juridique	$200,000

Neuroone Medical Technologies Corporation (NMTC) - Modèle d'entreprise: Strots de revenus

Ventes de dispositifs médicaux

Pour l'exercice 2023, Neuroone Medical Technologies Corporation a déclaré un chiffre d'affaires total de 1,47 million de dollars, principalement dérivé des ventes de dispositifs médicaux de leur technologie d'électrode corticale EVO.

Produit	Revenus (2023)	Segment de marché
Evo Cortical Electrode	1,47 million de dollars	Surveillance neurologique

Licence de technologie de surveillance neuronale

Neuroone a établi des accords de licence pour leur plateforme de surveillance neuronale.

• Revenus de licence pour 2023: 350 000 $
• Nombre de partenariats de licence actifs: 3

Services de conseil et de formation

La société fournit des services de conseil spécialisés liés aux technologies de surveillance neuronale.

Type de service	Revenus annuels	Clientèle
Conseil technique	$250,000	12 institutions médicales
Programmes de formation	$150,000	8 centres de recherche

Accords de collaboration de recherche

NeuroOne maintient des partenariats de recherche avec des établissements de recherche universitaires et médicaux.

• Financement total de collaboration de recherche en 2023: 500 000 $
• Nombre de partenariats de recherche actifs: 5

Revenus de redevances potentielles des portefeuilles de brevets

La société détient plusieurs brevets dans la technologie de surveillance neuronale.

Catégorie de brevet	Total des brevets	Revenu des redevances potentielles estimées
Technologie de surveillance neuronale	12 brevets actifs	175 000 $ Royalités annuelles prévues

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Value Propositions

You're looking at the core value NeuroOne Medical Technologies Corporation (NMTC) is delivering right now, late in 2025. It's all about making complex neurological procedures less invasive and more effective, and now expanding that core platform into chronic pain management.

Minimally Invasive Diagnostics: The foundation of the value proposition rests on high-definition sEEG (stereo-electroencephalography) electrodes designed for less invasive monitoring in epilepsy patients. This approach aims to improve the diagnostic phase of care compared to more traditional, potentially more invasive methods.

• Platform supports EEG recording, monitoring, ablation, drug delivery, and stimulation solutions.
• The technology is being developed for disorders like epilepsy, Parkinson's disease, dystonia, and essential tremors.

Single-System Solution: The OneRF™ Ablation system offers a unique advantage in the epilepsy space. It is the first and only device to receive FDA 510(k) clearance that combines both diagnostic and therapeutic applications within a single sEEG electrode. This capability allows for at-the-bedside ablation, which enhances versatility and convenience by avoiding separate procedures in different clinical settings. The technology provides monitoring, mapping, and ablation all in one system. This unique combination is a key differentiator for neurosurgeons using the platform.

Expanded Treatment Options: NeuroOne Medical Technologies Corporation expanded its platform significantly in August 2025 by receiving FDA 510(k) clearance for the OneRF® Trigeminal Nerve Ablation System. This system is designed to treat trigeminal neuralgia, a chronic facial pain condition. The target market is substantial, affecting approximately 150,000 people in the United States annually. The company is targeting a limited commercial launch for this pain management application in the fourth quarter of calendar 2025. This clearance leverages the existing OneRF® RF generator platform, marking the first step into broader pain management therapies beyond neurosurgery.

Improved Patient Outcomes: Clinical validation supports the efficacy of the OneRF® Ablation System in epilepsy treatment. For example, an early patient treated in June 2024, Clara, successfully surpassed the one year milestone of being seizure-free. Prior to treatment with the OneRF® platform, Clara was experiencing up to 10 seizures daily. Generally, the technology has demonstrated seizure reduction or complete seizure freedom for most patients that have received an ablation with the OneRF System. This translates directly into improved quality of life, allowing patients like Clara to enroll in college full-time and participate in previously hindered activities.

Here's a quick look at the financial performance supporting this commercialization effort as of late 2025. The preliminary unaudited product revenue for fiscal year 2025 reached a record $9.1 million, representing a 163% growth from the previous year. The company is debt-free and anticipates being fully funded through at least fiscal year 2026 following an $8.2 million capital raise in April 2025.

Metric	Value (As of Late 2025 Data)	Context/Period
FY 2025 Preliminary Product Revenue	$9.1 million	Fiscal Year 2025 (Preliminary, as of Oct 2025)
Product Revenue Growth (YoY FY2025 Guidance)	132% to 190% increase	Compared to FY 2024 Product Revenue of $3.5 million
Product Revenue (First Half FY 2025)	$4.7 million	97% increase YoY
Product Gross Margin (First Half FY 2025)	57.9%	Up from 27.9% in prior year period
Cash and Cash Equivalents	$6.6 million	As of September 30, 2025
Trigeminal Neuralgia Patient Population (US Annual)	Approximately 150,000	Target Market Size
OneRF Trigeminal Launch Target	Fourth Quarter of 2025	Limited Commercial Launch

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Customer Relationships

You're looking at how NeuroOne Medical Technologies Corporation (NMTC) manages its connections with the people who buy and use its technology. It's a mix of heavy-hitting partnerships and direct clinical engagement, which is typical when you're selling specialized medical devices.

Partner-managed relationship with Zimmer Biomet handling end-user sales

The relationship with Zimmer Biomet is central to getting the OneRF™ Ablation System into operating rooms. This is a classic distribution channel relationship, where a smaller innovator relies on a giant for scale. Zimmer Biomet, one of the largest global medical device companies in The United States, handles the commercialization exclusively across the U.S. and select international markets. This partnership kicked off with a significant financial component, as NeuroOne Medical Technologies Corporation received a $3.0 million upfront license payment in November 2024, which helped strengthen the balance sheet, leaving the company with no debt outstanding as of December 31, 2024.

The sales performance under this channel shows clear acceleration. For fiscal year 2024, product revenue was $3.5 million. The initial stocking orders with Zimmer Biomet were completed in the first quarter of fiscal 2025, where product revenue hit $3.3 million, a 235% increase year-over-year. The company is reiterating its full fiscal year 2025 product revenue guidance between $8.0 million and $10.0 million, representing a projected growth of 132% to 190% over fiscal year 2024. As of the third quarter of fiscal 2025, preliminary unaudited product revenue reached $9.1 million, showing 163% growth from the previous year.

This partnership also drives margin improvement. Product gross margin for fiscal year 2024 was 31%. For fiscal year 2025, the expectation is for product gross margins to range between 50% and 53%, up from the previous guidance of 47% to 51%. This compares favorably to the Q1 FY2025 product gross margin of 58.9%.

Here's a quick look at the financial impact of the Zimmer Biomet relationship:

Metric	FY 2024 Actual	FY 2025 Guidance (Reiterated Q3)	Q1 FY2025 Actual
Product Revenue (USD)	$3.5 million	$8.0 million to $10.0 million	$3.3 million
Product Gross Margin (%)	31%	50% to 53%	58.9%
Upfront License Payment (USD)	N/A	N/A	$3.0 million

Clinical support and training for neurosurgeons and hospital staff

The relationship extends beyond just delivery; it requires deep clinical integration. The OneRF ablation system is the first and only FDA-cleared product that uses the same sEEG electrode for both diagnostic and therapeutic applications in the brain. Clinical success is a key driver of adoption, with the majority of patients treated to date now being seizure free, and one patient reported seizure free for almost an entire year as of May 2025. Furthermore, a new ICD-10-PCS code for the 1RF ablation procedure became effective on October 1, 2024, which directly helps hospitals accurately report and process reimbursement claims.

NeuroOne Medical Technologies Corporation is focused on expanding the utility of its platform, which involves educating the clinical community:

• The OneRF ablation system is commercially available and treating epilepsy patients.
• The company has 3 FDA 510(k) cleared products for use in the brain.
• The company is planning additional submissions in 2025.

Direct engagement with key opinion leaders (KOLs) for clinical validation

Direct engagement with leading physicians is crucial for clinical validation and market acceptance. NeuroOne Medical Technologies Corporation utilizes discussions with neurosurgeon advisers who participated in their advisory board for brain ablation. This engagement is targeted toward expanding into new indications, such as trigeminal neuralgia, which affects roughly 150,000 people in the U.S. annually. The company was on track to submit its trigeminal nerve RF ablation 510(k) in the first half of 2025.

The broader medical affairs landscape shows that KOLs are increasingly relying on digital channels for knowledge. Proprietary research suggests that 54% of scientific knowledge gained by KOLs now stems from nonpersonal sources. This context shapes how NeuroOne Medical Technologies Corporation must approach its direct engagement strategy, balancing personal interactions with digital knowledge dissemination.

Investor relations and corporate updates for public shareholders

Maintaining transparency with public shareholders is a continuous effort, especially for a company that reported an EBITDA of -$11.64 million in the last twelve months (as of January 2025). The company communicates through formal filings and direct letters. A Letter to Shareholders was released on January 14, 2025, and an Investor Presentation was issued on May 13, 2025. A Virtual Investor Webinar was held on October 7, 2025.

Financially, the company bolstered its position by completing an oversubscribed capital raise in April 2025, totaling $8.2 million in net proceeds from institutional investors, which they believe funds the company through at least fiscal 2026. As of September 30, 2025, cash and cash equivalents stood at $6.6 million.

The ownership structure reflects significant retail investor interest:

• Share price as of November 21, 2025, was $0.64 / share.
• Approximately 61.30% of the stock is held by Public Companies and Individual Investors (retail).
• Institutional investors hold approximately 27.27% of the stock.
• There are 44 institutional owners and shareholders on record, holding a total of 14,703,530 shares.

Finance: draft 13-week cash view by Friday.

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Channels

You're looking at how NeuroOne Medical Technologies Corporation (NMTC) gets its OneRF® technology into the hands of surgeons and hospitals as of late 2025. The strategy heavily leans on a major established partner, but they're also pushing for direct market access with new indications.

Zimmer Biomet's established global sales and distribution network.

This partnership is the backbone for broad market reach. The expanded exclusive distribution agreement with Zimmer Biomet, one of the world's largest medical device manufacturers, is key to scaling up. This channel was immediately monetized; NMTC received a $3.0 million upfront payment from Zimmer Biomet, which was recognized in the first quarter of fiscal year 2025. This deal covers the exclusive commercialization of the OneRF™ Ablation System across U.S. and international markets, leveraging Zimmer Biomet's extensive channels.

Direct sales team for strategic accounts and partnership management.

While Zimmer Biomet handles much of the volume, a direct sales presence is necessary for managing the relationship and securing strategic accounts. This team also focuses on new product lines, like the recently cleared OneRF® Trigeminal Nerve Ablation System, where they continue ongoing discussions with strategic partners who may also use the existing OneRF® brain ablation system.

Medical conferences and trade shows for product awareness and training.

Product awareness and training rely on direct engagement at industry events. This channel is critical for educating the surgical community on the differentiated features of the OneRF® technology, such as the multi-contact RF probe that allows for both precise localization and tailored ablation under temperature-controlled conditions.

Regulatory submissions (e.g., FDA 510(k)) to enable market access.

Market access is gated by regulatory success, and NMTC has been hitting milestones. The company already had three product families that achieved FDA 510(k) clearance before the newest indication. The OneRF® Trigeminal Nerve Ablation System received U.S. Food and Drug Administration ("FDA") clearance on August 18, 2025, after the submission was completed in May 2025. This clearance targets the trigeminal neuralgia market, which is expected to grow from $262 million in 2024 to over $416 million by 2030. The company targeted a limited commercial launch for this new system in the fourth quarter of calendar year 2025.

Here's the quick math on how the channel performance is translating into financial results for the fiscal year 2025 guidance and Q1 actuals:

Metric	FY 2024 Actual	Q1 FY 2025 Actual	FY 2025 Guidance	FY 2025 Preliminary (as of Oct 2025)
Product Revenue (Millions USD)	$3.5	$3.3	$8.0 - $10.0	$9.1
Product Revenue YoY Growth	77% increase	235% increase (from $1.0M in Q1 2024)	132% - 190% increase	163% growth
Product Gross Margin	31%	58.9%	47% - 51%	N/A

The Q1 FY 2025 total revenue hit $6.3 million, which included that $3 million license payment from Zimmer Biomet. Still, the momentum from the core product sales is clear, with product revenue in Q1 reaching $3.3 million.

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Customer Segments

You're looking at the core groups NeuroOne Medical Technologies Corporation (NMTC) serves to drive its revenue, which, as of late 2025, is showing significant acceleration.

Neurosurgeons and Epileptologists: These are the primary clinical users who directly interact with the technology in the operating room. They are the champions for the OneRF® Ablation System, which is the first and only FDA-cleared single-electrode solution capable of both diagnostic recording and therapeutic ablation for epilepsy procedures. The positive clinical outcomes are a key driver for adoption; for instance, the first patient treated with the OneRF® Ablation System reached the milestone of over one year of seizure freedom. These specialists are also the target audience for the newly FDA-cleared OneRF® Trigeminal Nerve Ablation System, which received clearance on August 18, 2025.

Hospitals and Medical Centers: These entities are the purchasers of the capital equipment and the recurring disposable electrodes. Their decision-making is influenced by the system's ability to offer a better methodology, potentially reducing hospital stays and the number of surgeries required for a patient. The commercial traction is evident in the financial results; NeuroOne Medical Technologies Corporation reported preliminary unaudited product revenue for the fiscal year 2025 reached a record $9.1 million, a 163% growth from the previous year. For the third quarter of fiscal year 2025, product revenue was $1.7 million, up 105% year-over-year. The improved operational efficiency is reflected in the product gross margin expanding to 53.9% in Q3 2025.

Patients with Neurological Disorders: This segment represents the ultimate beneficiaries, primarily those with epilepsy, but increasingly those with trigeminal neuralgia and chronic pain. The company is targeting multiple billion-dollar markets with its minimally invasive approach. For the trigeminal neuralgia indication, where the OneRF® Trigeminal Nerve Ablation System is aimed, the therapeutics market is projected to grow from $262 million in 2024 to $416 million by 2030. Overall, the global neuralgia treatment market is estimated to be valued at USD 2.57 Bn in 2025.

The customer base is segmented by the product application and the purchasing entity, which can be summarized as follows:

Customer Segment Type	Primary Application/Role	Relevant Financial/Statistical Data Point
Clinical Users (Surgeons/Epileptologists)	Primary users of sEEG and Ablation Systems	One patient treated with OneRF® system achieved one year seizure freedom
Institutional Purchasers (Hospitals/Centers)	Purchasers of capital equipment and disposables	FY2025 Product Revenue Guidance range: $8.0 million to $10.0 million
Patients (Epilepsy/Trigeminal Neuralgia)	End-users benefiting from improved outcomes	Trigeminal Neuralgia Therapeutics Market projected to reach $416 million by 2030
Strategic Partners	Licensing and co-development entities	Received $3.0 million upfront license payment in Q1 2025 from Zimmer Biomet

Strategic medical device partners for licensing and co-development: This segment is crucial for scaling beyond direct sales, especially for new indications. The company has an expanded exclusive distribution partnership with Zimmer Biomet Holdings (ZBH). This relationship provided a significant financial boost, including a $3 million upfront license payment in the first quarter of fiscal 2025. Furthermore, NeuroOne Medical Technologies Corporation received its first order for its sEEG-based drug delivery system from a large biopharmaceutical company for preclinical research, opening a completely new market avenue. The company's ability to fund operations into at least fiscal year 2026 was bolstered by an oversubscribed capital raise totaling $8.2 million in April 2025.

The company's current focus is on expanding its cleared product families-it had three FDA-cleared product families as of early 2025-and leveraging these platforms across new customer segments like trigeminal neuralgia, with potential revenue generation anticipated in late calendar year 2025 if cleared.

• The OneRF® Ablation System for epilepsy is driving the core product revenue growth.
• The OneRF® Trigeminal Nerve Ablation System targets a market segment valued at $255.09 million in 2024 globally.
• The company reported cash and cash equivalents of $6.6 million as of September 30, 2025.
• The management team is also advancing development for spinal cord stimulation and drug delivery technologies, seeking further partnerships.

Finance: draft 13-week cash view by Friday.

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Cost Structure

You're looking at the costs NeuroOne Medical Technologies Corporation (NMTC) is managing as it scales its commercial efforts, and honestly, for a med-tech firm, the cost structure is heavily weighted toward future pipeline development and getting the current product into more hands.

High R&D expenses to fund pipeline development represent a necessary cash burn to secure future revenue drivers. For the first quarter of fiscal year 2025, Research & Development expense was reported at $1.2 million. This compares to $1.5 million in the same period of fiscal year 2024, showing a slight reduction in that specific quarter, though pipeline funding remains a core cost driver for the company's long-term value proposition. The ongoing work includes the 510(k) submission for the OneRF Trigeminal Nerve Ablation System, which carries associated development and submission costs.

Manufacturing and inventory costs for disposable electrodes are directly reflected in the product gross margin. Management has raised its full fiscal year 2025 guidance for product gross margin to range between 50% and 53%, up from the initial guidance of 47% to 51%. This margin improvement suggests increasing operating leverage and efficiency in manufacturing and inventory management as volumes rise. To give you a snapshot of the margin improvement trend, the product gross margin in Q1 FY2025 actually hit 58.9%, which is significantly higher than the 31% seen in fiscal year 2024.

Selling, General & Administrative (SG&A) expenses are a key component of operating costs. Specifically for Q1 FY2025, SG&A expense was $2.0 million, down from $2.2 million in Q1 FY2024. Looking at the first nine months of fiscal year 2025, total SG&A expense decreased 8% to $5.6 million compared to the prior year period. These costs cover commercialization activities, administrative overhead, and supporting the Zimmer Biomet distribution network.

To break down the total operating expenses for that key quarter, here's what the numbers looked like:

Expense Category	Q1 FY2025 Amount
Total Operating Expenses	$3.2 million
Research & Development Expense	$1.2 million
Selling, General & Administrative Expense	$2.0 million

The total operating expenses for Q1 FY2025 were $3.2 million, a decrease of 12% compared to $3.7 million in Q1 FY2024.

Regulatory compliance and patent maintenance costs are essential, though specific figures aren't always broken out separately in the top-line reports. These costs are embedded within the operating expenses, particularly R&D and SG&A, as NeuroOne Medical Technologies Corporation manages its intellectual property portfolio and seeks necessary clearances, such as the 510(k) submission for the trigeminal nerve ablation system.

• Ongoing costs support the existing OneRF Ablation system's regulatory status.
• Costs are incurred for new product submissions, like the trigeminal nerve system.
• Patent maintenance fees secure the company's core technology platform.

Finance: draft 13-week cash view by Friday.

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Revenue Streams

NeuroOne Medical Technologies Corporation (NMTC) revenue streams are primarily anchored in the sale of its medical devices and strategic partnership income.

The core product sales come from the OneRF™ Ablation System and the Evo sEEG electrodes, which are used for the surgical diagnosis and treatment of neurological disorders like epilepsy.

For the preliminary fiscal year 2025, the product revenue reached $9.1 million, representing a 163% year-over-year increase. This preliminary figure was within the initial full-year guidance range of $8.0 million to $10.0 million for product revenue.

A significant component of non-product revenue involves one-time license payments, such as the $3.0 million upfront payment received from Zimmer Biomet in relation to the expanded exclusive distribution agreement. The first quarter of fiscal year 2025 alone included this $3.0 million collaboration payment.

The Zimmer Biomet distribution agreement also creates a stream for potential future milestone payments, contingent upon the achievement of certain performance criteria.

Here's a quick look at some of the key revenue and guidance figures for the period:

Metric	Amount/Range	Period/Context
Preliminary FY2025 Product Revenue	$9.1 million	Fiscal Year 2025 (Preliminary)
FY2025 Product Revenue YoY Growth	163%	Compared to prior year
FY2025 Product Revenue Guidance Range	$8.0 million to $10.0 million	Fiscal Year 2025 Guidance
FY2025 Product Gross Margin Guidance Range	47% to 51%	Fiscal Year 2025 Guidance
License Revenue Recognized (YTD)	$3.0 million	First Nine Months of FY2025
Product Revenue (9 Months FY2025)	$6.4 million	First Nine Months of FY2025

The revenue streams can be broken down by source type:

• Product sales from the OneRF™ Ablation System and Evo sEEG electrodes.
• One-time license payments, like the $3.0 million received from Zimmer Biomet.
• Potential future milestone payments from the Zimmer Biomet distribution agreement.

To give you a sense of the growth trajectory, product revenue for the first six months of fiscal 2025 totaled $4.7 million, up from $2.4 million in the same period of 2024.

The company also reported cash and cash equivalents of $6.6 million as of September 30, 2025.

Finance: draft 13-week cash view by Friday.